DK3362445T3 - Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed - Google Patents
Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed Download PDFInfo
- Publication number
- DK3362445T3 DK3362445T3 DK16855690.0T DK16855690T DK3362445T3 DK 3362445 T3 DK3362445 T3 DK 3362445T3 DK 16855690 T DK16855690 T DK 16855690T DK 3362445 T3 DK3362445 T3 DK 3362445T3
- Authority
- DK
- Denmark
- Prior art keywords
- oxadiazolaminde
- inhibitors
- pharmaceutical composition
- histone deacetylase
- derivative compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150142014 | 2015-10-12 | ||
| PCT/KR2016/011355 WO2017065473A1 (en) | 2015-10-12 | 2016-10-11 | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3362445T3 true DK3362445T3 (da) | 2023-02-27 |
Family
ID=58517488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16855690.0T DK3362445T3 (da) | 2015-10-12 | 2016-10-11 | Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10494355B2 (da) |
| EP (1) | EP3362445B1 (da) |
| JP (1) | JP6697074B2 (da) |
| KR (1) | KR101839137B1 (da) |
| CN (1) | CN108699048B (da) |
| AU (1) | AU2016338118B2 (da) |
| CA (1) | CA3001666C (da) |
| DK (1) | DK3362445T3 (da) |
| ES (1) | ES2940413T3 (da) |
| FI (1) | FI3362445T3 (da) |
| HR (1) | HRP20230201T1 (da) |
| HU (1) | HUE061967T2 (da) |
| MX (1) | MX2018004447A (da) |
| MY (1) | MY196174A (da) |
| NZ (1) | NZ740809A (da) |
| PH (1) | PH12018500773B1 (da) |
| PL (1) | PL3362445T3 (da) |
| PT (1) | PT3362445T (da) |
| RU (1) | RU2695133C1 (da) |
| TW (1) | TWI694073B (da) |
| WO (1) | WO2017065473A1 (da) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2990165C (en) | 2015-02-02 | 2023-12-12 | Forma Therapeutics, Inc. | 3-aryl-4-amido-bicyclic [4,5,0]hydroxamic acids as hdac inhibitors |
| US10183934B2 (en) | 2015-02-02 | 2019-01-22 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors |
| RU2700696C2 (ru) | 2015-07-27 | 2019-09-19 | Чонг Кун Данг Фармасьютикал Корп. | 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция |
| MX2018001193A (es) | 2015-07-27 | 2018-05-22 | Chong Kun Dang Pharmaceutical Corp | Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. |
| RU2695227C9 (ru) | 2015-07-27 | 2020-03-04 | Чонг Кун Данг Фармасьютикал Корп. | Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция |
| DK3331864T3 (da) | 2015-08-04 | 2021-12-13 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse |
| EP3362445B1 (en) | 2015-10-12 | 2023-01-25 | Chong Kun Dang Pharmaceutical Corp. | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| KR102316234B1 (ko) * | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| WO2020127974A1 (en) | 2018-12-21 | 2020-06-25 | Bayer Aktiengesellschaft | 1,3,4-oxadiazoles and their derivatives as new antifungal agents |
| JP7470058B2 (ja) | 2019-01-30 | 2024-04-17 | 武田薬品工業株式会社 | 複素環化合物 |
| CN111848423B (zh) * | 2019-04-30 | 2022-10-14 | 尚科生物医药（上海）有限公司 | 3-氧代环丁基氨基甲酸叔丁酯的制备方法 |
| JP2022552444A (ja) * | 2019-09-27 | 2022-12-15 | 武田薬品工業株式会社 | Ｈｄａｃ６阻害剤として有用な２－イソインドール－１，３，４－オキサジアゾール誘導体 |
| JP2023508907A (ja) * | 2019-12-20 | 2023-03-06 | テナヤ セラピューティクス， インコーポレイテッド | フルオロアルキル－オキサジアゾールおよびその使用 |
| WO2021133957A1 (en) * | 2019-12-27 | 2021-07-01 | Onkure, Inc. | Benzimidazole compounds as hdac6 inhibitors |
| BR112022025710A2 (pt) | 2020-06-19 | 2023-03-07 | Bayer Ag | 1,3,4-oxadiazol pirimidinas e 1,3,4-oxadiazol piridinas como fungicidas |
| UY39276A (es) | 2020-06-19 | 2022-01-31 | Bayer Ag | Uso de compuestos de 1,3,4–oxadiazol–2–ilpirimidina para controlar microorganismos fitopatógenos, métodos de uso y composiciones. |
| UY39275A (es) | 2020-06-19 | 2022-01-31 | Bayer Ag | 1,3,4-oxadiazol pirimidinas como fungicidas, procesos e intermediarios para su preparación, métodos de uso y usos de los mismos |
| WO2021255091A1 (en) | 2020-06-19 | 2021-12-23 | Bayer Aktiengesellschaft | 1,3,4-oxadiazoles and their derivatives as fungicides |
| UY39277A (es) | 2020-06-19 | 2022-01-31 | Bayer Ag | Combinación de compuestos activos, método y uso de las mismas para controlar microorganismos dañinos y semilla tratada |
| CN116157398A (zh) | 2020-08-07 | 2023-05-23 | 意大发马克股份公司 | 作为组蛋白去乙酰化酶6(HDAC6)的选择性抑制剂用于治疗例如周围神经病变的2-(4-((5-(苯并[b]噻吩-3-基)-1H-四唑-1-基)甲基)苯基)-5-(二氟甲基)-1,3,4-噁二唑衍生物和类似化合物 |
| EP4308097A1 (en) * | 2021-03-15 | 2024-01-24 | The Regents Of The University Of Michigan | Non-hydroxamate hdac6 inhibitors and related methods of use |
| CA3215958A1 (en) | 2021-04-23 | 2022-10-27 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
| TW202308619A (zh) | 2021-05-04 | 2023-03-01 | 美商特納亞治療股份有限公司 | 用於治療代謝疾病和hfpef的hdac6抑制劑 |
| EP4355729A1 (en) | 2021-06-16 | 2024-04-24 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
| CN115572244B (zh) * | 2021-06-21 | 2024-04-30 | 复旦大学 | 2’-芳基查尔酮类化合物及其制备方法和在制药中的用途 |
| US20230322747A1 (en) * | 2022-04-08 | 2023-10-12 | Eikonizo Therapeutics, Inc. | Oxadiazole hdac6 inhibitors and uses thereof |
| WO2024033293A1 (en) * | 2022-08-08 | 2024-02-15 | Italfarmaco S.P.A. | Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors |
| CN115286615A (zh) * | 2022-09-01 | 2022-11-04 | 深圳市真味生物科技有限公司 | 一种消旋尼古丁的制备方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0276432A3 (de) | 1986-12-12 | 1988-10-26 | Ciba-Geigy Ag | Schädlingsbekämpfungsmittel |
| KR100265385B1 (ko) | 1998-02-27 | 2000-11-01 | 윤여표 | 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물 |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| EP1482940A2 (en) | 2001-10-03 | 2004-12-08 | Pharmacia Corporation | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| PT1465861E (pt) | 2001-12-20 | 2009-07-08 | Bristol Myers Squibb Co | Derivados de α-(n-sulfonamido)-acetamida como inibidores β-amilóides |
| CN101263121A (zh) | 2005-07-14 | 2008-09-10 | 塔克达圣地亚哥公司 | 组蛋白脱乙酰基酶抑制剂 |
| US20070037865A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| WO2007032445A1 (ja) * | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
| EP1996180B1 (en) | 2006-03-23 | 2011-08-03 | Biota Europe Ltd | Benzamide and pyridylamide derivatives as antibacterial agents |
| US20070293530A1 (en) | 2006-06-14 | 2007-12-20 | Methylgene Inc. | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors |
| EP1878730A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
| RU2482877C2 (ru) | 2006-12-11 | 2013-05-27 | Дженентек, Инк. | Композиции и способы для лечения опухоли |
| WO2008156726A1 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Inhibitors of janus kinases |
| WO2009010479A2 (en) | 2007-07-13 | 2009-01-22 | Euroscreen S.A. | Heterocyclic methylene piperidine derivatives and their use |
| KR100903743B1 (ko) | 2007-08-28 | 2009-06-19 | 전병태 | 소화기계 질환개선 및 예방용 식품 조성물 |
| WO2009032861A1 (en) | 2007-09-04 | 2009-03-12 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| CA2703718A1 (en) | 2007-11-02 | 2009-05-07 | Tammy Mallais | Inhibitors of histone deacetylase |
| JP5572095B2 (ja) | 2007-11-02 | 2014-08-13 | モメンタ ファーマシューティカルズ インコーポレイテッド | 非抗凝固性多糖組成物 |
| AU2009274549B2 (en) | 2008-07-23 | 2014-05-01 | Dana-Farber Cancer Institute, Inc. | Deacetylase inhibitors and uses thereof |
| US20120136003A1 (en) | 2009-04-20 | 2012-05-31 | Institute For Oneworld Health | Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
| WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| JP2011008205A (ja) | 2009-05-27 | 2011-01-13 | Fujifilm Corp | 二軸性光学異方性膜を作製するための組成物 |
| WO2011088192A1 (en) | 2010-01-13 | 2011-07-21 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| MX341133B (es) | 2010-01-13 | 2016-08-08 | Tempero Pharmaceuticals Inc * | Compuestos y metodos para la inhibición de hdac. |
| MX2012009829A (es) | 2010-02-25 | 2013-02-07 | Piramal Entpr Ltd | Compuestos de oxadiazol, su preparacion y uso. |
| AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| MX2012013081A (es) * | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| CA2820451C (en) | 2010-12-09 | 2017-12-12 | Wockhardt Limited | Ketolide compounds |
| KR101262870B1 (ko) | 2011-01-28 | 2013-05-09 | 환인제약 주식회사 | 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물 |
| ES2556822T3 (es) | 2011-07-08 | 2016-01-20 | Novartis Ag | Derivados de trifluorometil-oxadiazol novedosos y su uso en el tratamiento de enfermedad |
| EP2734500A4 (en) | 2011-07-20 | 2015-04-08 | Gen Hospital Corp | SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS |
| WO2013066839A2 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| BR112014012815A8 (pt) * | 2011-11-28 | 2017-06-20 | Novartis Ag | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença |
| EP2785720B1 (en) | 2011-11-29 | 2017-08-09 | Nanjing Allgen Pharma Co. Ltd. | Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
| SI3041828T1 (sl) | 2013-09-06 | 2018-10-30 | Aurigene Discovery Technologies Limited | 1,3,4-oksadiazolni in 1,3,4-tiadiazolni derivati kot imunomodulatorji |
| PT3080125T (pt) | 2013-12-12 | 2018-12-14 | Chong Kun Dang Pharmaceutical Corp | Novos derivados de azaindole como inibidores seletivos da histona-desacetilase (hdac) e composições farmacêuticas que compreendem os mesmos |
| CN104744446B (zh) * | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| ES2713700T3 (es) | 2014-11-24 | 2019-05-23 | Medifron Dbt Inc | Derivados de carboxamida y urea a base de oxazol y tiazol sustituidos como ligandos del receptor de vainilloide II |
| CN106349451B (zh) | 2015-07-14 | 2020-11-13 | 罗门哈斯公司 | 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法 |
| RU2695227C9 (ru) | 2015-07-27 | 2020-03-04 | Чонг Кун Данг Фармасьютикал Корп. | Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция |
| MX2018001193A (es) | 2015-07-27 | 2018-05-22 | Chong Kun Dang Pharmaceutical Corp | Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. |
| RU2700696C2 (ru) | 2015-07-27 | 2019-09-19 | Чонг Кун Данг Фармасьютикал Корп. | 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция |
| DK3331864T3 (da) | 2015-08-04 | 2021-12-13 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse |
| EP3362445B1 (en) | 2015-10-12 | 2023-01-25 | Chong Kun Dang Pharmaceutical Corp. | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
-
2016
- 2016-10-11 EP EP16855690.0A patent/EP3362445B1/en active Active
- 2016-10-11 CA CA3001666A patent/CA3001666C/en active Active
- 2016-10-11 NZ NZ740809A patent/NZ740809A/en unknown
- 2016-10-11 AU AU2016338118A patent/AU2016338118B2/en active Active
- 2016-10-11 HU HUE16855690A patent/HUE061967T2/hu unknown
- 2016-10-11 RU RU2018117502A patent/RU2695133C1/ru active
- 2016-10-11 PT PT168556900T patent/PT3362445T/pt unknown
- 2016-10-11 PL PL16855690.0T patent/PL3362445T3/pl unknown
- 2016-10-11 KR KR1020160131245A patent/KR101839137B1/ko active IP Right Grant
- 2016-10-11 MY MYPI2018701042A patent/MY196174A/en unknown
- 2016-10-11 HR HRP20230201TT patent/HRP20230201T1/hr unknown
- 2016-10-11 MX MX2018004447A patent/MX2018004447A/es unknown
- 2016-10-11 JP JP2018518487A patent/JP6697074B2/ja active Active
- 2016-10-11 CN CN201680072029.8A patent/CN108699048B/zh active Active
- 2016-10-11 DK DK16855690.0T patent/DK3362445T3/da active
- 2016-10-11 FI FIEP16855690.0T patent/FI3362445T3/fi active
- 2016-10-11 US US15/763,972 patent/US10494355B2/en active Active
- 2016-10-11 WO PCT/KR2016/011355 patent/WO2017065473A1/en active Application Filing
- 2016-10-11 ES ES16855690T patent/ES2940413T3/es active Active
- 2016-10-12 TW TW105132939A patent/TWI694073B/zh active
-
2018
- 2018-04-10 PH PH12018500773A patent/PH12018500773B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI3362445T3 (fi) | 2023-03-21 |
| CN108699048B (zh) | 2021-12-28 |
| ES2940413T3 (es) | 2023-05-08 |
| US20180273495A1 (en) | 2018-09-27 |
| PL3362445T3 (pl) | 2023-08-07 |
| HRP20230201T1 (hr) | 2023-03-31 |
| RU2695133C1 (ru) | 2019-07-22 |
| KR101839137B1 (ko) | 2018-03-26 |
| WO2017065473A1 (en) | 2017-04-20 |
| TW201716397A (zh) | 2017-05-16 |
| MX2018004447A (es) | 2018-08-01 |
| JP2018530571A (ja) | 2018-10-18 |
| CA3001666A1 (en) | 2017-04-20 |
| AU2016338118A1 (en) | 2018-04-12 |
| MY196174A (en) | 2023-03-20 |
| BR112018007289A2 (pt) | 2018-10-23 |
| NZ740809A (en) | 2019-04-26 |
| PH12018500773A1 (en) | 2018-10-29 |
| US10494355B2 (en) | 2019-12-03 |
| CA3001666C (en) | 2021-03-30 |
| AU2016338118B2 (en) | 2019-03-14 |
| PT3362445T (pt) | 2023-03-20 |
| KR20170043091A (ko) | 2017-04-20 |
| PH12018500773B1 (en) | 2018-10-29 |
| TWI694073B (zh) | 2020-05-21 |
| EP3362445A1 (en) | 2018-08-22 |
| HUE061967T2 (hu) | 2023-09-28 |
| EP3362445B1 (en) | 2023-01-25 |
| EP3362445A4 (en) | 2019-05-22 |
| CN108699048A (zh) | 2018-10-23 |
| JP6697074B2 (ja) | 2020-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3362445T3 (da) | Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed | |
| DK3328843T3 (da) | 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning | |
| DK3331864T3 (da) | 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse | |
| DK3330259T3 (da) | 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne | |
| HK1251549A1 (zh) | 作為組蛋白去乙酰酶6抑制劑的1，3，4-噁二唑磺酰胺衍生物及含其的醫藥組合物 | |
| DK3328849T5 (da) | 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer | |
| DK3297605T3 (da) | Topiske, farmaceutiske sammesætninger | |
| BR112016018062A2 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
| DK3513809T3 (da) | Medicinsk sammensætning, som omfatter tivozanib | |
| DK3412660T3 (da) | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme | |
| HK1251556A1 (zh) | 用作選擇性組蛋白脫乙酰酶抑制劑的雜環烷基衍生化合物及含其的藥物組合物 | |
| IL248785B (en) | Antecedents of ]-n5,1-dimethyl3--oxo-(3,2-dihydro-h1-pyrazol-4-yl)]-methyl-isoxazole-3-carboxamide and pharmaceutical preparations including these antecedents | |
| DK3464260T3 (da) | Forbindelser, der indeholder ureamotiver, og derivater deraf som antibakterielle lægemidler | |
| BR112017013012A2 (pt) | compostos de indenil, composições farmacêuticas e usos médicos destes | |
| DK3383397T3 (da) | Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin | |
| DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
| DK3389633T3 (da) | Farmaceutiske sammensætninger, der omfatter phenylaminopyrimidinderivat | |
| DK3229843T3 (da) | Farmaceutisk sammensætning, præparat og anvendelser deraf | |
| DK3157506T3 (da) | Smagsmaskeret oral, farmaceutisk sammensætning | |
| DK3455216T3 (da) | Pyridinylderivater, farmaceutiske sammensætninger og anvendelser deraf som aoc3-inhibitorer | |
| DK4056557T3 (da) | Benzazepinderivater nyttige som medikamenter | |
| DK4023651T3 (da) | Optisk aktivt pyranochromenylphenolderivat og farmaceutisk sammensætning, der omfatter samme | |
| DK3288933T3 (da) | Oxindolforbindelser og farmaceutiske sammensætninger deraf | |
| DK3313370T3 (da) | Oftalmologisk farmaceutisk sammensætning | |
| DK3302483T3 (da) | Farmaceutiske sammensætninger og anvendelse deraf |